A Model for Parkinson Disease: Administration of Rotenone by Using Microvesicles

ARCE MA. ELENA; BRUERA, MANUEL; CIUFFO GM; SANCHEZ, SUSANA I.

Córdoba

Congreso; XXXIII Congress of the Argentine Society for Research in Neuroscience; 2018

Sociedad Argentina de Neurocienccias

Parkinson?s disease (PD) is one of the most frequent neurologicaldiseases in elderness. Rotenone is an herbicideknown to produce neurotoxic effects. Several methods ofdelivery have been explored, some of them with high mortality.Thus, we decided to administer rotenone by usingmicrovesicles of a copolymer of PLGA. Microvesicles allowa slow delivery of the drug and thus a long treatment with asingle dose administration. Resuspended microvesicles (25mm) were administered by subcutaneous injection in a doseof 50 mg/kg. Rats were weighted every day, and no significantdifference with control animals was observed during thewhole treatment at the dose assayed. Animal?s behaviorwas evaluated by using the bar test, grid test, and rearingtest. Significant changes were observed on behavior testsafter 5 weeks of treatment (p < .01) for the three testassayed. Latency in the behavior during the bar and gridtest do correlate with catalepsy. Rigidity was tested withthe rearing test. Physiological symptoms such as rigidityand immobility did appear after 5 weeks of treatment. Anaccurate experimental model of PD should reproduce theslow, progressive, and selective nigrostriatal dopaminergicdegeneration seen in the disease. The lack of mortality inthe treated group supports a good selection in the dose ofrotenone applied. Although nigrostriatal degeneration canbe confirmed by the specific staining, the behavioral resultsstrongly suggest that animals developed PD.